title: Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria.
abstract: This report describes a pilot study, conducted in Nigeria, of the World Health Organization protocol for monitoring human immunodeficiency virus (HIV) drug resistance (HIVDR) and associated program factors among patients receiving first-line antiretroviral therapy (ART). In 2008, 283 HIV-infected patients starting ART were consecutively enrolled at 2 ART clinics in Abuja. Twelve months after ART initiation, 62% were alive and on first-line ART, 3% had died, 1% had transferred out of the program, and 34% were lost to follow-up. Among patients on first-line ART at 12 months, 90% had viral suppression. However, in view of the high loss to follow-up rate (34%), strategies for patient retention and tracking are critical to minimize possible HIVDR and optimize treatment outcomes.
authors.affiliation: CDC-Nigeria, Centers for Disease Control and Prevention, Abuja.
authors.forename: Richard
authors.initials: R
authors.lastname: Ugbena
authors.forename: John
authors.initials: J
authors.lastname: Aberle-Grasse
authors.forename: Karidia
authors.initials: K
authors.lastname: Diallo
authors.forename: Orji
authors.initials: O
authors.lastname: Bassey
authors.forename: Tapdiyel
authors.initials: T
authors.lastname: Jelpe
authors.forename: Erin
authors.initials: E
authors.lastname: Rottinghaus
authors.forename: Aderemi
authors.initials: A
authors.lastname: Azeez
authors.forename: Raphael
authors.initials: R
authors.lastname: Akpan
authors.forename: Mukhtar
authors.initials: M
authors.lastname: Muhammad
authors.forename: Vedapuri
authors.initials: V
authors.lastname: Shanmugam
authors.forename: Satvinder
authors.initials: S
authors.lastname: Singh
authors.forename: Chunfu
authors.initials: C
authors.lastname: Yang
mesh_terms: D000328:Adult; D000554:Ambulatory Care Facilities; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D005260:Female; D005500:Follow-Up Studies; D006678:HIV / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D006801:Humans; D008297:Male; D009549:Nigeria / Q000453:epidemiology; D016896:Treatment Outcome; D019562:Viral Load / Q000706:statistics & numerical data; D014944:World Health Organization
chemical_list: D019380:Anti-HIV Agents